SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
Key Highlights
- ➤SpyGlass Pharma (SGP) acquires AVS for approximately $13 million in cash
- ➤AVS secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma
- ➤BIM-IOL System is supplied by AVS in two Phase 3 registrational trials
- ➤AVS will exclusively manufacture several IOL types for Santen commercialization in Japan
- ➤Acquisition accelerates premium toric and extended depth-of-focus lens development
Expert Statements
Patrick Mooney, CEO of SpyGlass Pharma
“The acquisition of AVS for SpyGlass Pharma is strategically important as it secures our long-term supply of world class IOLs.”
Patrick Mooney, CEO of SpyGlass Pharma
“Not only are we owning significant manufacturing capability of approved IOL material, trusted and widely adopted by surgeons worldwide, but we are also positioning ourselves to accelerate production of a portfolio of lenses that we believe can fit our drug delivery pads.”
Patrick Mooney, CEO of SpyGlass Pharma
“While our monofocal IOL addresses the vast majority of the glaucoma and ocular hypertension patients with cataracts, some of these patients can benefit from premium IOL options like toric and extended depth-of-focus lenses.”
Patrick Mooney, CEO of SpyGlass Pharma
“This is a major step toward delivering on these aspirations, while maintaining our strategy, focus and existing cash runway.”
Rie Nakajima, Director of the Board and Chief Operating Officer of Santen Global
“AVS has built a strong reputation for innovation, quality, and manufacturing excellence.”
Rie Nakajima, Director of the Board and Chief Operating Officer of Santen Global
“We believe SpyGlass Pharma is well positioned to leverage these strengths to maximize the value of innovative products and further advance efforts to address unmet needs in eye care around the world.”
* SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL) * Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL System * Accelerates pathway to adding premium lens options into its IOL-based drug delivery system * SpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other global IOL companies IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd (Santen) and is the current supplier of SpyGlass Pharma’s IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System.
Get started
Create a free account to read the full story.